A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

NCT02439970 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated early due to results from another CMX001 study

Conditions

Cytomegalovirus Disease

Interventions

DRUG: Brincidofovir
DRUG: Valganciclovir

Sponsor

Jazz Pharmaceuticals